What do Myelofibrosis Tests Tell Your Doctor? with Dr. Srinivas Tantravahi

Golcadomide ± Rituximab in Relapsed/Refractory Large B-cell Lymphoma | Julio Chavez, MD, MS | #ASH24

Mosunetuzumab + Polatuzumab Shows Promising Outcomes in LBCL | Julio Chavez, MD, MS | #ASH24

The Iron Survivor: Chronic Lymphocytic Leukemia Patient Spotlight Pratik Desai

Factors Influencing Enrollment in Hematologic Cancer Trials (2008-2023) | Rupayan Kundu, MD | #ASH24

Barriers to Stem Cell Transplant in #AML: NC Cohort Insights | Michele Sainvil, MD | #ASH24

Fresh Start 2025: Manage Nutrition Side Effects from AML Care with Science-Based Strategies

TP53-Mutated AML & MDS: Why Clinical Trials Are Your Best Option | Dan Link, MD | #ASH24

Adding Menin Inhibitors in Combination Therapy for AML Patients | Amir Fathi, MD | #ASH24

Promising Early Results from Menin Inhibitors for Treating AML | Harry Erba, MD | #ASH24

Promising Results for CAR-T Cell therapy for Follicular Lymphoma | Matthew Frank, MD, PhD | #ASH24

A Conversation about the Phase III SENTRY Trial for Myelofibrosis with Dr. John Mascarenhas

ACA Changes and Medicaid Expansion: What Blood Cancer Patients Need to Know and How to Stay Prepared

Allogeneic & Autologous Stem Cell Transplant for Follicular Lymphoma | Yasmina Serroukh, MD | #ASH24

Odronextamab as First-Line Therapy in Follicular Lymphoma | Ruemu Birhiray, MD | #ASH24

Phase 3 Asciminib Tolerability Trial , ASC4FIRST, for Patients with CML | David Andorsky |#ASH2024

The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024

Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24

Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24

BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024

Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24

Quality of Life Dispairities for Patients with MDS | Somedeb Ball, MBBS | #ASH24

Importance of Support for Caregivers of Transfusion Dependent Patients | Maria Diez-Campelo | #ASH24

Benefits of Thorough Evaluations Before Starting AML Treatment | Samuel Yates, MD, MS | #ASH24

Impact of Transplant Timing in MDS Treatment | Benajmin Rolles, MD | #ASH24

How Self-Rated Health Impacts Patient Outcomes| Nora Balas, PhD | #ASH24

Examining 3 Key Studies on Treatments for AML and ALL | Jayastu Senapati, MD, MBBS | #ASH24

Inpatient or Outpatient Consolidation Therapy: Which is Better?| Leora Boussi, MD | #ASH24

Racial Disparities in Youth and Young Adults with AML | Erin Feliciano, MD | #ASH24

AML: New Strategies For Preventing Graft vs Host Disease | Giorgia Battipaglia, MD | #ASH24

Revumenib: New Approved Drug for Relapsed/Refractory Acute Leukemia Patients | Eytan Stein | #ASH24

Impact of Hospital Readmission on Quality of Life in AML | Ayobami Olafimihan, MD | #ASH24

Good Responses to Phase 2 CLIA + Ven Therapy for Acute Myeloid Leukemia | Tapan Kadia, MD | #ASH24

Menin Inhibitor Study Results: Ziftomenib for Newly Diagnosed AML Patients | Amer Zeidan | #ASH24

VEN + IVO + AZA Combination Therapy in IDH1-Mutated AML, MDS & MPNs | Jennifer Marvin Peek | #ASH24

CAR-T Cell Therapy for Transformed Follicular Lymphoma | Matthew Cortese, MD | #ASH24

Bispecific Antibodies for Diffuse large B-cell lymphoma with Lorenzo Falchi, MD

Adding a FLT3 Inhibitor May Improve Chemo Efficacy for Newly Diagnosed AML | Musa Yilmaz, MD| #ASH24

Real-World Impact of CAR-T Therapy on DLBCL: Insights & Future Research | Lisa Herms, PhD | #ASH24

Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD | #ASH24

Fludarabine vs. Bendamustine Lymphodepletion Prior to CAR-T for LBCL | Alaa Ali, MD | #ASH24

Rituximab for Low Tumor Burden Follicular Lymphoma | Noriko Fukuhara MD, PhD | #ASH24

Positive Loncastuximab & Rituximab Results in R/R Follicular Lymphoma | Juan Alderuccio, MD | #ASH24

Treatment Outcomes for LBCL with Central Nervous System Involvement | Juan Alderuccio, MD | #ASH24

Venetoclax + Pola-R-CHP for High-Risk B-Cell Lymphoma | Catherine Diefenbach, MD | #ASH24

Glofit-R-ICE for Patients with Relapsed/Refractory DLBCL | Catherine Diefenbach, MD | #ASH24

Bispecific Antibody Use After CAR-T Failure for B-Cell Lymphoma | Megan Melody, MD, MS | #ASH24

Safety of CAR-T Therapy, Tisa-cel, for DLBCL | Christian Chabannon, MD, PhD | #ASH24

Moving the Diffuse Large B-Cell Lymphoma Field Forward | Matthew Matasar, MD | #ASH24

Safety & Efficacy of Odronextamab for DLBCL After CAR-T Failure | Matthew Matasar, MD | #ASH24

Ketogenic Diet During CAR-T Therapy for DLBCL | Christopher D'Angelo, MD | #ASH24

Boom-Boom Radiation as Bridging Therapy Prior to CAR-T for DLBCL | Christopher D'Angelo, MD | #ASH24

A Faster Tandem CAR T-Cell Product, Zamto-Cel Being Studied in DLBCL | Nirav Shah, MD, MSHP | #ASH24

Bispecific Antibody, AZD0486 Attacks a New Target in DLBCL | Sameh Gaballa, MD | #ASH24

Exploring Barriers to CAR T-Cell Therapy in Blood Cancer Patients | Yannis Valtis, MD | #ASH24

Glofitamab for Relapsed/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24

Are Stem Cell Transplants Safe for Myelofibrosis Patients Over 70? | Muhammad Umair Mushtaq | #ASH24

A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24

Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24

Promising Results for Odronextamab in Post CAR T Patients with DLBCL | Jennifer Crombie, MD | #ASH24